CAS: 608137-33-3; (2S)-2,6-Diamino-N-[(2S)-1-Phenylpropan-2-Yl]Hexanamide,Methanesulfonic Acid
- 英文名称(2S)-2,6-Diamino-N-[(2S)-1-Phenylpropan-2-Yl]Hexanamide,Methanesulfonic Acid
- 中文名称甲磺酸赖氨酸安非他命
- 其它别名(2S)-2,6-DIAMINO-N-[(1S)-1-METHYL-2-PHENYLETHYL]HEXANAMIDE DIMETHANESULFONATE; Lisdexamfetamine dimesylate; Ldx; Lisdexamfetamine mesilate; Lisdexamfetamine mesylate
- CAS编号608137-33-3
- MFCD编号:MFCD16628114
- FDA UNII编号:SJT761GEGS
- 分子式:C16H29N3O4S分子量:359.49
- 产品CID: 1589274
- 产品分类生物化工 → 氨基酸及其衍生物 → 赖氨酸类衍生物
MSDS等安全信息
合成工艺路线路线简述
📜N,N'-二叔丁氧羰基-L-赖氨酸 N-丁二酰亚胺酯置于n-甲基吗啉,Palladium On Activated Charcoal,氢气体系中,用 1,4-二氧六环,异丙醇 作为反应溶剂,25.0 °C,275.8 Kpa 条件下,反应 4.0H,反应生成 赖氨酸安非他命甘露醇马利兰
参考文献: Process For Preparation Of Lisdexamphetamine[fr] Procédé De Préparation De Lisdexamphétamine
标题: Process For Preparation Of Lisdexamphetamine[fr] Procédé De Préparation De Lisdexamphétamine
海关参考信息
- 2902600000-乙苯
2912110000-甲醛
2912120000-乙醛
2921211000-乙二胺 - 💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
- 详情请参考：📖 海关编码查询和海关进出口税则
专利信息
专利号:US-11717498-B2
优先权日:2013-12-31
标题 :Methods of treatment using amphetamine controlled release, prodrug, and abuse deterrent dosage forms
发明人：POPP KARL; MECKLER HAROLD
权利人:Chemapotheca LLC; PHARMAPOTHECA A INC
摘要:The invention also relates to pharmaceutical compositions comprising highly pure amphetamine and amphetamine-class compounds resulting from the synthesis of chiral and racemic amphetamine derivatives by stereospecific, regioselective cuprate addition reaction with aziridine phosphoramidate compounds, and to methods of manufacturing, delivering, and using the amphetamine compounds resulting from the synthesis of chiral and racemic amphetamine derivatives by stereospecific, regioselective cuprate addition reaction with aziridine phosphoramidate compounds.
专利号:US-12208068-B2
优先权日:2013-12-31
标题:Amphetamine controlled release, prodrug, and abuse-deterrent dosage forms
发明人：POPP KARL; MECKLER HAROLD
权利人:PHARMAPOTHECA A INC
摘要:The invention also relates to processes for producing abuse deterrent pharmaceutical compositions comprising highly pure amphetamine and amphetamine-class compounds resulting from the synthesis of chiral and racemic amphetamine derivatives by stereospecific, regioselective cuprate addition reaction with aziridine phosphoramidate compounds, and to methods of manufacturing, delivering, and using the amphetamine compounds resulting from the synthesis of chiral and racemic amphetamine derivatives by stereospecific, regioselective cuprate addition reaction with aziridine phosphoramidate compounds.
专利号:WO-2010042120-A1
优先权日:2008-10-09
标 题 :Process for the synthesis of amphetamine derivatives
供应商参考报价(招募中)
品牌试剂参考报价(招募中)
📌 第三方产品分析报告
合成参考文献
参考文献:10.1055/s-0031-1273223
摘要:Franke AG, Konrad A, Lieb K, Huss M. [Stimulant and non-stimulant medication in current and future therapy for ADHD]. Fortschr Neurol Psychiatr. 2012 Mar;80(3):130–40. doi: 10.1055/s-0031-1273223.
参考文献:10.1517/14656566.2013.754013
摘要:Wigal SB, Raja P, Shukla A. An update on lisdexamfetamine dimesylate for the treatment of attention deficit hyperactivity disorder. Expert Opin Pharmacother. 2013 Jan;14(1):137–45. doi: 10.1517/14656566.2013.754013.
参考文献:10.1186/2050-6511-13-18
摘要:Babcock T, Dirks B, Adeyi B, Scheckner B. Efficacy of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder previously treated with amphetamines: analyses from a randomized, double-blind, multicenter, placebo-controlled titration study. BMC Pharmacology and Toxicology. 2012 Dec 19;13(1):18. doi: 10.1186/2050-6511-13-18.
参考文献:10.1177/02698811211032475
摘要:Heal DJ, Smith SL. Prospects for new drugs to treat binge-eating disorder: Insights from psychopathology and neuropharmacology. J Psychopharmacol. 2021 Jul 28;36(6):680–703. doi: 10.1177/02698811211032475.
参考文献:10.1517/14656566.9.9.1565
摘要:Faraone SV. Lisdexamfetamine dimesylate: the first long-acting prodrug stimulant treatment for attention deficit/hyperactivity disorder. Expert Opin Pharmacother. 2008 Jun;9(9):1565–74. doi: 10.1517/14656566.9.9.1565.
📝 需求与反馈
尽可能描述清楚需求与问题信息
